Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer

Inclusion Criteria: * Age: 18-75 years old, male or female * Histologically confirmed diagnosis of colorectal adenocarcinoma with a phase II or III disease, within 2 months from radical resection, and intends to receive 6 months of adjuvant chemotherapy with mFOLOFX6 or XELOX, without adjuvant radiation indications * No prior any level of peripheral nerve system disease * Patients have not received any other possible neurotoxic-reaction-causing drugs (such as oxaliplatin, cisplatin and paclitaxel drugs etc) * With the capability to accurately record the occurrence and severity of neurotoxicity by questionnaire * With normal functions of major organs * No contraindication to chemotherapy * Life expectancy ≥ 3 months * Patients have provided a signed Informed Consent Form Exclusion Criteria: * Patients who received radical resection, but are expected not be able to complete 6 months of adjuvant chemotherapy * Patients who receive palliative chemotherapy * Patients who need adjuvant or palliative radiotherapy during chemotherapy * Be allergic to GM1 * Hereditary abnormal metabolism of glucose and lipid * Doctors believe that patients are not suitable for receiving GM1 treatment * With confirmed history of neurological or psychiatric disorders, including epilepsy and dementia * With concomitant diseases that will seriously harm the patients' safety or impact the completion of the study * Patients (male or female) have fertility possibility but not willing or not to take effective contraceptive measures